Drug resistance mechanism and optimization strategy of BCMA CAR-T cell therapy
10.12354/j.issn.1000-8179.2023.20230950
- VernacularTitle:BCMA CAR-T细胞治疗的耐药机制及优化策略研究
- Author:
Yunjia LI
1
;
Zhuogang LIU
;
Rong HU
Author Information
1. 中国医科大学附属盛京医院第一血液内科 沈阳市 110000
- Keywords:
multiple myeloma;
chimeric antigen receptor T cells(CAR-T);
drug resistance;
immune escape;
bone marrow microenviron-ment
- From:
Chinese Journal of Clinical Oncology
2023;50(21):1115-1118
- CountryChina
- Language:Chinese
-
Abstract:
Chimeric antigen receptor T cell(CAR-T)therapy has produced remarkable results in the treatment of hematological tumors.The BCMA antigen is widely expressed on the surface of multiple myeloma cells and is a suitable,efficient target for CAR-T therapy.BCMA CAR-T cell therapy has a high response rate for relapsed or refractory patients in particular,and CAR-T cells are still detectable in most patients 1 year after infusion.However,drug resistance and disease recurrence remain key problems in clinical management.In this paper,we discuss the response factors and resistance induction mechanism of BCMA CAR-T cell therapy from several perspectives,such as the immune es-cape of multiple myeloma cells,CAR-T product factors,previous treatment regimens,and tumor immune microenvironment inhibition.We also propose possible optimization strategies in order to provide reference for future exploration.
